Boyapati A, et al. High Baseline Serum IL-6 Identifies a Subgroup of Rheumatoid Arthritis Patients with Rapid Joint Damage and Clinical Progression and Predicts Increased Sarilumab Treatment Response. ACR 2018, abstract L08.
EULAR-aanbevelingen over CVRM bij reumatische en musculoskeletale aandoeningen
feb 2022 | Jicht, Sclerodermie, Sjögren, SLE